Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study

Area of Science:

• Rheumatology
• Pulmonology
• Clinical Pharmacology

Background:

• Systemic sclerosis (SSc) is a complex autoimmune disease often leading to interstitial lung disease (ILD).
• Limited data exists on the efficacy of various therapies for ILD in SSc patients.

Purpose of the Study:

• To evaluate the potential benefits of SSc management therapies on patients with interstitial lung disease.
• To identify which treatments may improve pulmonary function in SSc-ILD.

Main Methods:

• Retrospective observational study of SSc patients with forced vital capacity (FVC) < 70% predicted.
• Patients were grouped by treatment: high-dose prednisone, other immunosuppressives, cyclophosphamide (CYC), D-penicillamine, or no drug.
• Pulmonary function changes were analyzed by FVC improvement and rate of change; bronchoalveolar lavage was performed in a subset.

Main Results:

• Of 122 eligible patients, 14 received CYC. The CYC group showed significantly greater FVC improvement compared to other treatment groups.
• Patients with early-stage disease demonstrated a higher likelihood of responding to any drug therapy.
• No significant differences were observed in FVC changes for prednisone, other immunosuppressives, D-penicillamine, or no-drug groups.

Conclusions:

• Cyclophosphamide treatment was associated with significant improvement in FVC in SSc patients with ILD.
• Early disease presentation appears to predict better treatment response.
• Prospective controlled trials of CYC in early SSc-ILD are needed to confirm its efficacy in altering disease progression.